A citation-based method for searching scientific literature

Alice Boilève, Loïc Verlingue, Antoine Hollebecque, Valérie Boige, Michel Ducreux, David Malka. Expert Opin Investig Drugs 2021
Times Cited: 4







List of co-cited articles
33 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
100

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng,[...]. Cancer Discov 2017
378
100

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
413
75

Genomic spectra of biliary tract cancer.
Hiromi Nakamura, Yasuhito Arai, Yasushi Totoki, Tomoki Shirota, Asmaa Elzawahry, Mamoru Kato, Natsuko Hama, Fumie Hosoda, Tomoko Urushidate, Shoko Ohashi,[...]. Nat Genet 2015
608
75

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Jesus M Banales, Vincenzo Cardinale, Guido Carpino, Marco Marzioni, Jesper B Andersen, Pietro Invernizzi, Guro E Lind, Trine Folseraas, Stuart J Forbes, Laura Fouassier,[...]. Nat Rev Gastroenterol Hepatol 2016
603
75

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
275
75

New Horizons for Precision Medicine in Biliary Tract Cancers.
Juan W Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X Zhu. Cancer Discov 2017
251
75

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
449
75

Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes.
Mina Komuta, Olivier Govaere, Vincent Vandecaveye, Jun Akiba, Werner Van Steenbergen, Chris Verslype, Wim Laleman, Jacques Pirenne, Raymond Aerts, Hirohisa Yano,[...]. Hepatology 2012
210
50

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Arndt Vogel, Stefan Kasper, Michael Bitzer, Andreas Block, Marianne Sinn, Henning Schulze-Bergkamen, Markus Moehler, Nicole Pfarr, Volker Endris, Benjamin Goeppert,[...]. Eur J Cancer 2018
34
50

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Jeeyun Lee, Se Hoon Park, Heung-Moon Chang, Jun Suk Kim, Hye Jin Choi, Myung Ah Lee, Joung Soon Jang, Hei Cheul Jeung, Jung Hun Kang, Hyun Woo Lee,[...]. Lancet Oncol 2012
301
50

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J W Valle, I Borbath, S A Khan, F Huguet, T Gruenberger, D Arnold. Ann Oncol 2016
305
50

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Benjamin R Kipp, Jesse S Voss, Sarah E Kerr, Emily G Barr Fritcher, Rondell P Graham, Lizhi Zhang, W Edward Highsmith, Jun Zhang, Lewis R Roberts, Gregory J Gores,[...]. Hum Pathol 2012
157
50

Molecular profile of BRCA-mutated biliary tract cancers.
Gilbert Spizzo, Alberto Puccini, Joanne Xiu, Richard M Goldberg, Axel Grothey, Anthony F Shields, Sukeshi Patel Arora, Moh'd Khushman, Mohamed E Salem, Francesca Battaglin,[...]. ESMO Open 2020
35
50

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Oliver Clements, Joseph Eliahoo, Jin Un Kim, Simon D Taylor-Robinson, Shahid A Khan. J Hepatol 2020
117
50

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Daniela Sia, Yujin Hoshida, Augusto Villanueva, Sasan Roayaie, Joana Ferrer, Barbara Tabak, Judit Peix, Manel Sole, Victoria Tovar, Clara Alsinet,[...]. Gastroenterology 2013
311
50

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Yasuhito Arai, Yasushi Totoki, Fumie Hosoda, Tomoki Shirota, Natsuko Hama, Hiromi Nakamura, Hidenori Ojima, Koh Furuta, Kazuaki Shimada, Takuji Okusaka,[...]. Hepatology 2014
289
50

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010
50

Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.
Chirag Nepal, Colm J O'Rourke, Douglas V N P Oliveira, Andrzej Taranta, Steven Shema, Prson Gautam, Julien Calderaro, Andrew Barbour, Chiara Raggi, Krister Wennerberg,[...]. Hepatology 2018
64
50

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
540
50

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Sarina A Piha-Paul, Do-Youn Oh, Makoto Ueno, David Malka, Hyun Cheol Chung, Adnan Nagrial, Robin K Kelley, Willeke Ros, Antoine Italiano, Kazuhiko Nakagawa,[...]. Int J Cancer 2020
120
50

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
768
50

Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Angela Lamarca, Jorge Barriuso, Mairéad G McNamara, Juan W Valle. J Hepatol 2020
126
50

Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Jesus M Banales, Jose J G Marin, Angela Lamarca, Pedro M Rodrigues, Shahid A Khan, Lewis R Roberts, Vincenzo Cardinale, Guido Carpino, Jesper B Andersen, Chiara Braconi,[...]. Nat Rev Gastroenterol Hepatol 2020
441
50

Mismatch Repair Protein Deficiency/Microsatellite Instability Is Rare in Cholangiocarcinomas and Associated With Distinctive Morphologies.
Jennifer Y Ju, Megan E Dibbern, Mani S Mahadevan, Jinbo Fan, Paul R Kunk, Edward B Stelow. Am J Clin Pathol 2020
8
50

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.
Tanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse, Tatsuya Ioka, Davide Melisi, Teresa Macarulla, John Bridgewater, Harpreet Wasan,[...]. Future Oncol 2020
46
50

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C Newton, Huiling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C Burn. Cancer Discov 2021
42
50

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William P Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh,[...]. Br J Cancer 2019
164
50

Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
Sarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, Cedric Chuan Young Ng, Jason Yongsheng Chan, Vikneswari Rajasegaran, Tse Hui Lim, Kiat Hon Lim, Su Pin Choo, Simona Dima,[...]. JCO Glob Oncol 2020
13
50

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
221
50

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Milind Javle, Maeve Lowery, Rachna T Shroff, Karl Heinz Weiss, Christoph Springfeld, Mitesh J Borad, Ramesh K Ramanathan, Lipika Goyal, Saeed Sadeghi, Teresa Macarulla,[...]. J Clin Oncol 2018
323
50

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
Antonella De Luca, Riziero Esposito Abate, Anna Maria Rachiglio, Monica Rosaria Maiello, Claudia Esposito, Clorinda Schettino, Francesco Izzo, Guglielmo Nasti, Nicola Normanno. Int J Mol Sci 2020
32
50

Targeting FGFR inhibition in cholangiocarcinoma.
Lipika Goyal, Sarinya Kongpetch, Valerie E Crolley, John Bridgewater. Cancer Treat Rev 2021
26
50

Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma.
Judith Meza-Junco, Aldo J Montano-Loza, Vickie E Baracos, Carla M M Prado, Vincent G Bain, Crystal Beaumont, Nina Esfandiari, Jessica R Lieffers, Michael B Sawyer. J Clin Gastroenterol 2013
158
25

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, Giovanni Brandi. Medicines (Basel) 2020
10
25

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.
Sergey V Silkin, Sergey S Startsev, Marina E Krasnova, Grigory A Raskin, Natalia V Mitiushkina, Aglaya G Iyevleva, Anna P Sokolenko, Evgeny N Imyanitov. J Gastrointest Cancer 2016
10
25

A population based analysis of prognostic factors in advanced biliary tract cancer.
Renata D'Alpino Peixoto, Daniel Renouf, Howard Lim. J Gastrointest Oncol 2014
25
25

Potential survival benefit of radiofrequency ablation for small solitary intrahepatic cholangiocarcinoma in nonsurgically managed patients: A population-based analysis.
Lu Wu, Diamantis I Tsilimigras, Ayesha Farooq, J Madison Hyer, Katiuscha Merath, Anghela Z Paredes, Rittal Mehta, Kota Sahara, Feng Shen, Timothy M Pawlik. J Surg Oncol 2019
12
25

Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Timothy Kendall, Joanne Verheij, Eugenio Gaudio, Matthias Evert, Maria Guido, Benjamin Goeppert, Guido Carpino. Liver Int 2019
97
25

CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications.
Kamile Gul, Sevinc Nas, Didem Ozdemir, Mehmet Gumus, Reyhan Ersoy, Bekir Cakir. Am J Med Sci 2011
26
25

Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher. Immunity 2018
764
25

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
D Yoshikawa, H Ojima, M Iwasaki, N Hiraoka, T Kosuge, S Kasai, S Hirohashi, T Shibata. Br J Cancer 2008
282
25

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
25

Epidemiology and Risk Factors of Cholangiocarcinoma.
Martha M Kirstein, Arndt Vogel. Visc Med 2016
80
25


Molecular Pathogenesis of Cholangiocarcinoma.
Peter L Labib, George Goodchild, Stephen P Pereira. BMC Cancer 2019
98
25

Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Francesca V Negri, Barbara Dal Bello, Camillo Porta, Nicoletta Campanini, Sandro Rossi, Carmine Tinelli, Guido Poggi, Gabriele Missale, Silvia Fanello, Stefania Salvagni,[...]. Liver Int 2015
39
25

Detection of circulating tumor cells in cancers of biliary origin.
Omar Al Ustwani, Dan Iancu, Rabi Yacoub, Renuka Iyer. J Gastrointest Oncol 2012
29
25

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Leigh Marcus, Steven J Lemery, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2019
424
25

Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.
Halim Charbel, Firas H Al-Kawas. Curr Gastroenterol Rep 2011
73
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.